This makes it a promising target for immunotherapies as illustrated by the approval of CD38-specific monoclonal antibodies daratumumab and isatuximab by the FDA for the treatment of relapsed MM patients (8–10). The gene discussed is CD38; the disease is Miyoshi myopathy.